» Articles » PMID: 12594515

CD4+ T Cells Are Required for Secondary Expansion and Memory in CD8+ T Lymphocytes

Overview
Journal Nature
Specialty Science
Date 2003 Feb 21
PMID 12594515
Citations 659
Authors
Affiliations
Soon will be listed here.
Abstract

A long-standing paradox in cellular immunology concerns the conditional requirement for CD4+ T-helper (T(H)) cells in the priming of cytotoxic CD8+ T lymphocyte (CTL) responses in vivo. Whereas CTL responses against certain viruses can be primed in the absence of CD4+ T cells, others, such as those mediated through 'cross-priming' by host antigen-presenting cells, are dependent on T(H) cells. A clearer understanding of the contribution of T(H) cells to CTL development has been hampered by the fact that most T(H)-independent responses have been demonstrated ex vivo as primary cytotoxic effectors, whereas T(H)-dependent responses generally require secondary in vitro re-stimulation for their detection. Here, we have monitored the primary and secondary responses of T(H)-dependent and T(H)-independent CTLs and find in both cases that CD4+ T cells are dispensable for primary expansion of CD8+ T cells and their differentiation into cytotoxic effectors. However, secondary CTL expansion (that is, a secondary response upon re-encounter with antigen) is wholly dependent on the presence of T(H) cells during, but not after, priming. Our results demonstrate that T-cell help is 'programmed' into CD8+ T cells during priming, conferring on these cells a hallmark of immune response memory: the capacity for functional expansion on re-encounter with antigen.

Citing Articles

Dendritic cell immunotherapy has its antitumor action improved by the LPS in the maturation process.

Lopes A, Vieira J, da Silva S, Murta E, Michelin M Clin Transl Oncol. 2025; .

PMID: 39979657 DOI: 10.1007/s12094-025-03858-5.


Immunological pathogenesis and treatment progress of adenovirus pneumonia in children.

Liang Y, Wei J, Shen J, Liang Z, Ma X, Du Y Ital J Pediatr. 2025; 51(1):4.

PMID: 39789604 PMC: 11715079. DOI: 10.1186/s13052-024-01836-1.


Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.

Wu S, Ho C, Yang J, Yu S, Lin Y, Lin S Clin Transl Med. 2024; 15(1):e70149.

PMID: 39715697 PMC: 11666332. DOI: 10.1002/ctm2.70149.


Computational analysis of the functional impact of MHC-II-expressing triple-negative breast cancer.

Cui Y, Zhang W, Zeng X, Yang Y, Park S, Nakai K Front Immunol. 2024; 15:1497251.

PMID: 39664386 PMC: 11631845. DOI: 10.3389/fimmu.2024.1497251.


Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies.

Tao Z, Chyra Z, Kotulova J, Celichowski P, Mihalyova J, Charvatova S Blood Cancer J. 2024; 14(1):213.

PMID: 39627220 PMC: 11615218. DOI: 10.1038/s41408-024-01193-6.